Aesthetic treatment around the eyes—here's what you should know
In a since-deleted TikTok video, California-based ceramic artist and product designer Esther Jeong recently took to the platform to share her story: Having travelled to South Korea to undergo the popular Juvelook treatment—an injectable designed to boost the skin's collagen—she immediately experienced a loss of vision in her left eye when the treatment was administered. Despite being quick to raise concern with her doctor, she was reassured that it was a temporary side effect.
Devastatingly, it turned out to be the opposite. Later seeking emergency treatment and consultation with ophthalmologists, Jeong was informed that branch arteries in her eyes had been blocked, leading to dead retinal tissue. Infuriatingly, Jeong was also told that her vision could've been saved had the treatment been reversed within two hours of being administered.
'I'm a designer and I'm a ceramic artist, and my livelihood is based off of what I see,' Jeong tearfully explained. Though she is now seeking compensation, the damage left by what Jeong thought was 'a very harmless skin booster' will endure. View this post on Instagram
A post shared by Dr. Muneeb Shah (@doctorly)
Aesthetic treatments are only becoming more popular, including those performed on the delicate eye area and treatments involving overseas travel. Vogue Singapore reached out to Dr Stephanie Ho, consultant dermatologist at Stephanie Ho Dermatology, for her advice on the risks and precautions to keep in mind when seeking these treatments. The eyes have it
'Aesthetic treatments to rejuvenate the thin skin area around eyes are commonly performed, as these areas often show signs of ageing earlier,' Ho explains. Such signs include eyelid laxity, fine lines, or a 'hollowing' appearance due to reduced fat and elasticity in the area.
Ho offers a rundown of the most common eye area treatments, including their potential side effects and precautions to take: Botox
What does it target? The appearance of crow's feet and frown lines, and promoting a brow lift effect.
Potential side effects Bruising, ptosis (upper eyelid drooping), dry eyes, heaviness of the brows or eyes, and headaches.
How can I minimise the risks? 'Go to a trained and experienced injector who administers such procedures regularly,' says Ho. 'Avoid blood thinning medications before treatment, and avoid pressure applied to the face and strenuous exercise in the first 24 hours after treatment.' Fillers
What does it target? Volume loss under the eyes and dark circles.
Potential side effects Bruising, bumps and lumpiness, the Tyndall effect (a blue tinge under the skin) and vascular occlusion (though rare, this can lead to blindness).
How can I minimise the risks? Again, Ho stresses the importance of seeing a trained, experienced injector. 'Their use of a blunt cannula is generally safer than when sharp needles are used,' Ho advises, while cautioning against fillers to high-risk areas such as the nose area, glabella and forehead. Ho also recommends avoiding permanent fillers: 'When dissolvable fillers are used, their effects can be reversed using hyaluronidase.' If you experience side effects including pain, blanching, a mottled skin appearance or changes to your vision, seek medical help immediately. Laser or micro needling treatments
What does it target? Improving skin texture, pigmentation, the appearance of wrinkles, and skin tightening.
Potential side effects Redness, swelling, crusting, infection, hyper- or hypopigmentation, scarring, burns or—in rare cases—eye injury.
How can I minimise the risks? You guessed it—as always, your choice of injector is key 'to ensure appropriate parameters and adequate intervals between treatments. Avoid excessive treatments with intervals that are too short—this can impair the skin barrier and cause sensitivity or side effects.' Sun exposure should be avoided before or after treatment, while it's of course essential to follow the pre- and post-care instructions given.
'Avoid inexperienced clinicians or unlicensed individuals who offer cheap prices, promise unrealistic results and use pressurising sales tactics,' says Ho of selecting the professional you work with. The skin around the eye area is thin and delicate, making it a part of the face that is commonly targeted when seeking aesthetic treatments. However, precautions should be taken. Frank Flores What conversations should I be having?
'An experienced and ethical clinician will be open and forthcoming about pre- and post-care, set realistic expectations, and address any safety concerns,' says Ho. 'They will be happy to answer any questions during the consultation and will not be pressurising, giving patients plenty of time to consider whether or not to proceed with treatment.'
Points that an experienced clinician will cover with their patients include: What concern/s is the patient hoping to address?
Realistic expectations about results.
Any underlying medical conditions, as well as side effects the patient may have previously experienced with aesthetic treatments.
Current medications such as blood thinners or retinoids.
Potential risks, complications and side effects will be discussed. The clinician should provide a breakdown of common risks, as well as rare but serious side effects (for example, vascular occlusion that may lead to blindness.)
Patients should feel free to ask questions, express any concerns, and have open and detailed discussions without being rushed or pressured. Ho recommends making sure the following questions are addressed: Who will be performing the procedure?
How many times have they performed the treatment?
Ask to see 'before' and 'after' photos if available.
What are the common side effects? Have serious side effects ever occurred? How were they managed?
How long is the treatment and what are the immediate side effects?
What is the downtime and what kind of recovery is expected?
Who should I contact if side effects occur, including out of hours? What side effects are normal?
Of course, with any aesthetic treatment, experiencing side effects is likely—it's most important to know what's to be expected, and therefore what isn't.
'For injectables such as Botox or fillers, normal side effects include mild swelling, tenderness or bruising at injection sites, and slight asymmetry or lumpiness early on as the filler settles in—especially for thinner-skinned areas such as under the eyes,' Ho shares. Most side effects will resolve within one to two weeks.
Meanwhile, normal side effects of lasers and micro needling include redness, peeling or crusting, skin sensitivity, and pinkness of the skin. Similarly, most of these side effects should recede within a one- to two-week timeframe.
Having an established idea of what side effects to expect before undergoing your treatment will help to provide ease of mind should you notice them, while making it easier to note what is out of the ordinary and therefore requires attention. Ho advises medical attention should be sought for side effects including: Severe or worsening pain in a localised area
Sudden vision changes, including double vision or problems with eye movement
Blanching (whitening) or unusual discolouration of skin, such as a mottled appearance
Progressive redness, pain, warmth or pustules
Fever or chills
Numbness or muscle weakness that does not improve
Worsening symptoms
'An experienced clinic will often provide their patients with a leaflet detailing the potential side effects of their specific treatment,' reiterates Ho. 'There will also be contact information for during and after office hours, while the clinic may contact their patients within 24 hours of the treatment to ensure there are no concerns. A patient shouldn't hesitate to contact their clinic for reassurance if they have worries about anything at all.'
Above all, as Ho's advice reflects, 'going to a trained and experienced specialist is the best way of minimising the risk of potential side effects.' Aesthetic treatments are becoming increasingly commonplace, and their benefits should outweigh the risks. While placing faith in a professional, keep yourself as informed as possible, and follow your instincts should something feel off. You may be the patient—but an ideal procedure will be in collaboration with you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
2 hours ago
- Straits Times
First China weight loss drug emerges
Obesity drugmakers Novo Nordisk and Eli Lilly & Co. now face their first serious rival in China. PHOTO: REUTERS Hong Kong – Novo Nordisk and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide, a turning point in China's efforts to combat rising obesity and diabetes rates with local innovation. With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly's blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world's second-largest economy. China's nascent weight loss drug market is poised for rapid growth, with analysts estimating it could grow to between US$5.6 billion (S$7.2 billion) and US$11.4 billion a year. While China still accounts for just a fraction of the projected US$150 billion global pie, a raft of homegrown treatments and cheaper generics could significantly improve the availability – and affordability – of the medication. The country has a pipeline of more than 30 late-stage obesity drug candidates under development, according to LEK Consulting. Several firms have already licensed their drugs to US or European drugmakers like AstraZeneca and Merck & Co for further clinical development outside the country. Local biotech firms are promising to overcome the limitations of current treatments, including creating long-awaited GLP-1 pills that are just as effective and safe as weekly injections peddled by Novo and Lilly. Leading insulin producer Gan & Lee Pharmaceutical is pushing ahead a longer-acting drug that can be taken every two weeks, instead of weekly. Laekna is developing a treatment that would help patients preserve more muscle – a common concern among GLP-1 takers – while still losing fat. Hangzhou Sciwind Biosciences expects China will approve its drug ecnoglutide, which led to more than 15 per cent weight loss after 48 weeks when given at the highest dose, in early 2026. 'Multiple Chinese biopharma are developing differentiated and competitive candidates and have the potential to lead the direction of weight loss drug research and development,' said Chen Chen, head of China healthcare research at UBS Securities. Competition is expected to ramp up next year when cheaper alternative versions of semaglutide – the active ingredient in Novo's Wegovy – launch after semaglutide's China patent expires. Their emergence could pressure drugmakers to lower their treatment prices, and could quickly expand access to the drugs across a country of 1.4 billion people. Compared to Western countries where popular GLP-1 drugs are widely available for people looking to lose weight, the current penetration rate for such drugs in China is 'extremely low,' said UBS's Mr Chen. Novo only started rolling out obesity treatments in China in 2024, and Lilly earlier this year. A government-led campaign to curb obesity and establish new weight management clinics has fuelled demand, which is now outstripping supply and leading to stock shortages, said Shawn Qu, chief of SinoUnited Health's Endocrinology, Metabolism and Thyroid Center in Shanghai. 'It's far from meeting the clinical need,' said Mr Qu, who's also an adviser to China's National Health Commission weight management committee. Foreign medicines have long enjoyed higher trust and recognition in China, where the local biotech industry is still overcoming past quality issues. Skepticism about the quality of domestic generic medicines also remains high among Chinese – and rare backlash from doctors earlier this year fuelled questions about whether government efforts to slash treatment prices had come at the cost of efficacy. The relative price differences between foreign and domestic weight loss drugs could be much smaller than in PD-(L)1 medicines used to treat cancer, added Yang Huang, senior analyst for China healthcare research at JP Morgan. 'We think foreign companies could be more willing to lower prices for their weight loss drugs in China,' he said, 'as we have seen in the US market where major weight loss drug players have started engaging in price competition.' Going forward, 'you'll see a lot more competitors in the China market versus anywhere else,' said Justin Wang, head of LEK's China practice. 'It will be unlikely for one or two companies to dominate the whole market.' BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
CNA
2 days ago
- CNA
What is tapping, and can it really improve mental health?
It looks a little goofy. A self-help method called ' tapping,' which involves using the fingertips to perform acupressure while countering negative emotions with breathing exercises and positive affirmations, has elicited eye-rolls from some mental health professionals. 'I'm safe in my car,' a woman on TikTok says as she practises the technique, using a finger to tap the top of her head, then the side of her eyebrow and the middle of her chin. 'I am my safe space.' In the video, she explains that driving by herself is a struggle, but tapping has helped lower her anxiety and refocus her thoughts. Anecdotes like this are easy to find on social media. Over the last 15 years or so, tapping has also popped up on wellness podcasts, TV shows and even the best-seller list. As a result, the practice, also known as the Emotional Freedom Technique or EFT, has attracted a devoted following and become a big business. But many experts remain skeptical. WHERE DID TAPPING COME FROM? Tapping, which falls under the umbrella of energy psychology, originated from a technique called Thought Field Therapy developed by the psychologist Roger Callahan in the 1980s. He conceived of it while working with a patient who had a severe phobia of water, which Dr Callahan tried treating in various ways, including exposure therapy by the pool. One day, when the patient complained that just looking at the water gave her a stomachache, Dr Callahan told her to tap firmly under her eye, an area he knew to be associated with the ' stomach meridian ' in traditional Chinese medicine. According to Dr Callahan, after two minutes of tapping, the patient declared her stomachache had disappeared, along with her fear of the water. Dr Callahan developed Thought Field Therapy from there, contending that some patients required a series of acupressure points to be touched in a specific order. Thought Field Therapy was discredited by psychology experts, in part because there isn't a way to measure energy meridians, nor any evidence that proves they exist. But in the 1990s, Gary Craig, a Stanford graduate who later became an ordained minister, rebranded the technique, creating a simplified version called EFT. Proponents suggest that tapping not only relieves stress and anxiety but can also improve symptoms of depression, post-traumatic stress disorder, addiction and chronic pain, among other maladies. Practitioners now pay hundreds of dollars to take EFT courses or pursue an official certification. DOES IT WORK? Even though there are more than 200 studies that examine meridian tapping, this body of work is not as robust as it might sound. Research that claims to highlight the effectiveness of EFT has been riddled by conflicts of interest, small sample sizes, statistical errors and a lack of rigour. For these reasons, prominent members of the American Psychological Association have said that the push to popularise EFT is based on pseudoscience. 'When you really look at the evidence, it falls apart,' said Cassandra L Boness, an assistant professor of psychology at the University of New Mexico and the lead author of a peer-reviewed commentary published in 2024 that raised concerns about the quality of EFT research and questioned the effectiveness of the technique. But that isn't to say that EFT is useless, experts said. Those who try the technique are instructed to think about or do activities they may find scary or uncomfortable – a form of exposure therapy, which is a powerful way of regulating emotions. Tapping also involves taking a moment to explore one's thoughts, which therapists say can help people understand their behavior. In essence, tapping is 'a hodgepodge of interventions, some of which are, I'm sure, quite effective,' said David F Tolin, the director of the Anxiety Disorders Center at the Institute of Living in Hartford, Connecticut. But there isn't high-quality research to show that tapping itself is the active ingredient, he added. WHAT'S THE HARM? Despite the lacklustre evidence, some patients and therapists insist tapping truly helps. 'It doesn't replace existing best practises for treating PTSD, depression, addictions or other serious conditions,' said David Feinstein, who offers classes and certifications in energy medicine, along with his wife. But, in his opinion, it can make those treatments more effective. Melissa Lester, a psychotherapist in Sandy Springs, Georgia, said she found tapping could provide quick benefits, including a calmer, clearer mind. She decided to become certified in the technique because she wanted to give her clients an alternative when methods offered by other therapists, like cognitive behavioural therapy, didn't produce the desired results. Providing an alternative treatment can indeed be useful to patients, Dr Boness said, but she questioned whether it was ethical to do so in the absence of rigorous scientific evidence. Her 'biggest fear,' she added, was that vulnerable people would turn to tapping, and then find that it doesn't work. 'It's not actually a psychological treatment,' she said.
Business Times
3 days ago
- Business Times
CCCS okays Tamarind Health's proposed acquisition of TalkMed
[SINGAPORE] The Competition and Consumer Commission of Singapore (CCCS) has cleared Tamarind Health's proposed acquisition of tertiary healthcare service provider TalkMed Group on Friday (Jun 27). The competition watchdog assessed that the proposed transaction will not substantially lessen competition within the Singapore market. TW Troy, a special purpose vehicle managed by Tamarind Health, proposed to privatise mainboard-listed TalkMed by way of scheme of arrangement, at S$0.456 per share, on Dec 23, 2024. CCCS said it commenced its review on Jan 13 to see whether the proposed privatisation would infringe Section 54 of the Competition Act 2004, which prohibits mergers that may substantially lessen competition. It conducted a public consultation from Jan 21 to 31, seeking feedback from stakeholders such as the involved parties' competitors and insurance service providers. Based on its assessment of the parties' submissions and third-party feedback, CCCS concluded that the proposed transaction is unlikely to substantially lessen competition in Singapore in relation to the supply of private medical oncology services. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Medical oncology refers to the field of medicine that deals with the treatment of cancer primarily with drugs, such as chemotherapy. CCCS reasoned that patients can choose alternative providers of medical oncology services in both public and private sectors in Singapore, limiting the impact of the proposed merger. Furthermore, it added that any increase in the parties' market power upon the proposed transaction would likely be constrained by insurers – who play a 'significant role' in affecting how patients select and finance private medical oncology services – as well as the regulatory framework governing the healthcare sector in Singapore. Tamarind is a pan-Asian oncology-focused group headquartered in Singapore. It is controlled by alternative asset manager Templewater and its affiliates. As part of the deal, 65 Equity Partners, a Singapore-based global investment firm backed by Temasek, will subscribe for shares in Tamarind Health through its local enterprise fund. After the transaction, 65 Equity Partners will hold about 18.3 per cent of the voting interest in Tamarind Health, while doctor shareholders will hold about 31.3 per cent. Shares of TalkMed closed flat at S$0.45 on Friday, before CCCS' announcement.
